REBECCA ELLSPERMANN: Open Payments
NPI 1083857429 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,029 in 129 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $2,174 · 2025 $3,029
Food & beverage: $2,731Education: $299
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $419 |
| ABBVIE INC. | 26 | $407 |
| Regeneron Healthcare Solutions, Inc. | 13 | $370 |
| UCB, Inc. | 17 | $362 |
| Galderma Laboratories, L.P. | 17 | $251 |
| Janssen Biotech, Inc. | 5 | $240 |
| Novartis Pharmaceuticals Corporation | 9 | $188 |
| E.R. Squibb & Sons, L.L.C. | 6 | $183 |
| Arcutis Biotherapeutics, Inc. | 1 | $122 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
Products named: DUPIXENT, Bimzelx, NEMLUVIO, RINVOQ, TREMFYA, Sotyktu, SKYRIZI, Zoryve.
Industry payments across TX — which companies pay providers there.
